News & Updates
Filter by Specialty:
Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata
Use of ivarmacitinib 4- and 8-mg doses for 24 weeks eases hair loss and is generally tolerated in patients with moderate or severe alopecia areata (AA), a phase II study has shown.
Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata
27 Oct 2023
DAPT after PCI: Fracture risk lower with ticagrelor vs clopidogrel in Chinese ACS patients
A territory-wide, retrospective cohort study in Hong Kong has shown that dual antiplatelet therapy (DAPT) with ticagrelor is associated with a lower risk of major osteoporotic fractures (MOF) than clopidogrel in Chinese patients with acute coronary syndrome (ACS) who underwent first-ever percutaneous coronary intervention (PCI).
DAPT after PCI: Fracture risk lower with ticagrelor vs clopidogrel in Chinese ACS patients
27 Oct 2023
High red meat consumption increases risks of CVD and diabetes
Higher consumption of both unprocessed and processed red meat is associated with higher risks of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM), according to a meta-analysis involving >4.4 million people by researchers from the University of Hong Kong (HKU).
High red meat consumption increases risks of CVD and diabetes
27 Oct 2023
Histologic margin status predicts relapse in lentigo maligna melanoma
Histologic margin status shows a robust association with progression for lentigo maligna melanoma, suggest the results of a recent study.
